Gastric cancer (GC) presents a significant health challenge and ranks as the fifth most common cancer in the world. Unfortunately, most patients with GC exhaust standard care treatment options due to late diagnosis and tumour heterogeneity that leads to drug resistance, resulting in poor survival outcomes. Potentially, this situation can be improved by personalising treatment choice. Organoids are an emerging cell model system that recapitulates tumour heterogeneity and drug responses. Coupled with genomic analysis, organoid culture can be used to guide personalised medicine. The GC organoid field, however, lacks standardised methodologies for assessing organoid drug sensitivities. Comparing results across different GC organoid studies and correlating organoid drug responses with patient outcomes is challenging. Hence, we aim to summarise the methodologies used in GC organoid drug testing and correlation with clinical outcomes and discuss design considerations and limitations to enhance the robustness of such studies in the future.
6 April 2026 in European Journal of Medicinal Chemistry
Herein, we report the discovery of APO-50815 (14), a potent and selective thietane-3-ol WEE1 inhibitor. When tested against TP53-mutated colorectal cancer (CRC) patient-derived organoids (PDOs) grown from peritoneal and liver metastases, 14 exhibited outstanding anticancer efficacy, surpassing previously reported branched alkane counterpart 3, as well as clinical candidates AZD1775 (1) and ZN-c3 (2). Against primary CRC organoids with diverse TP53, BRAF and KRAS mutation profiles compared with patient-matched normal colon organoids, 14 exhibited selectively potent activity, yielding exceptionally high TI values (129-238) that highlight a substantial therapeutic window for potential cancer treatment. Against primary CRC PDOs (TP53-WT, BRAF-V600E, KRAS-WT), 14 profoundly elevated DNA damage and replication stress compared to 1, while amplifying cellular apoptosis, confirming a broadly similar but superior mode of action. Owing to its highly selective and exemplary anticancer efficacy, 14 represents a valuable tool compound for drug testing investigations against primary and metastatic CRCs, especially in the context of PDOs.
14 May 2026 in European Journal of Surgical Oncology
Gastric cancer with peritoneal metastases remains a major clinical challenge, with poor prognosis and limited benefit from systemic therapy. PIPAC is an emerging locoregional option used mainly in the palliative setting, however international practice remains heterogenous, particularly with respect to patient selection, chemotherapy regimens, and response assessment. This study aimed to capture international practice patterns and identify areas of consistency, variation and evidence gaps in the use of PIPAC for gastric cancer. A 44-question online survey was distributed electronically via the International Society for the Study of Pleura and Peritoneum (ISSPP) and directly to expert clinicians involved in the use of PIPAC for gastric cancer management. The survey examined clinician and centre-level practices pertaining to patient selection, intraperitoneal chemotherapy protocols and perceived utility and limitations of this approach in managing gastric cancer. Complete responses were obtained from 80 clinicians representing 62 centres across 28 countries. Marked international variability was observed in patient selection, treatment intent, and response assessment. However, several areas of consistencies were identified, including predominant use of cisplatin/doxorubicin-based regimens, similar procedural approaches, and reliance on intraoperative, radiological, and pathological regression grading to assess treatment response. Lack of high-quality prospective evidence was consistently identified as the principal barrier to broader adoption and standardisation. This international survey provides comprehensive insight into clinician decision making in the use of PIPAC for gastric cancer. The findings demonstrate heterogeneity and emerging areas of practice convergence, and may inform pathway development, priorities for prospective research and future standardisation efforts.
Macrocyclization can enhance the selectivity of acyclic compounds toward structurally similar biological targets such as kinases. WEE1 regulates cellular homeostasis and is a promising target in oncology. The clinical candidate AZD1775 (1) failed to progress past Phase II trials because of patient tolerability issues, likely due to off-target inhibition of polo-like kinase 1 (PLK1). Herein, a computer-aided drug design approach was conducted to develop a macrocycle based on the 1-WEE1 X-ray cocrystal structure. Significantly enhanced WEE1 inhibitory selectivity over PLK1 was determined for leading macrocycle 2, which also demonstrated broader kinome-wide selectivity. Patient-derived organoids from colorectal cancer (CRC) peritoneal and liver metastases, treated with 2, demonstrated comparably strong or enhanced anticancer efficacy compared to that of 1. Against patient-matched normal colon vs primary CRC organoids, 2 potently and selectively treated CRC, as well as enhanced DNA damage compared to 1. Finally, the X-ray cocrystal structure of 2 bound to WEE1 validated its computationally predicted bioactive binding mode.